Lajme nga Bota

The newest vaccine is called Valneva: How it was created and why Britain broke the order agreement

The newest vaccine is called Valneva: How it was created and why Britain broke

Another anti-Covid vaccine called Valneva. It was created in Scotland by the French firm Valneva. But it has not recently received approval to be used in Britain, and this was confirmed today by the Minister of Health Sajid Javid. The British government had envisioned multi-dose orders but withdrew from the deal. The reasons are said to be more commercial than for effectiveness against Covid.

The newest vaccine is called Valneva: How it was created and why Britain broke

"There are commercial reasons why we canceled the contract, but what I can tell you is that it was also clear to us that the vaccine in question that the company was developing would not get approval from the MHRA here in Britain. This is something for him. which we will work together to see what we can do more " said the minister.

The Financial Times reported that in a recent trial in Britain, it was found that the Valneva vaccine was less effective than some other vaccines. However, this vaccine has not yet completed all clinical trials and trials. However, the breach of the agreement with Britain is also related to the reasons for Brexit and the problems that may arise with the supply chain.

In September 2020 Valneva announced that the British government had ordered 60 million doses of its vaccine and had invested in its manufacturing plant-Livingston.

How is it created?

The Valneva vaccine uses the inactivated Covid-19 virus in a manner similar to influenza vaccines, and some experts see it as having the potential to be the most effective vaccine against rivals, as it uses a new technology. But it seems British institutions are still unsure. Shares in Valneva fell 35% on Monday after it was announced that the British government had broken the deal worth up to 1.4 billion euros.

* BBC article, translated and adapted into Albanian by Tiranapost.al.